Afry AB (AFXXF) Q2 2026 Earnings Call Transcript

AFRY reported Q2 2026 order backlog up 8% YoY to SEK 22.4B and noted improved utilization after 14 quarters of decline, but current results remain soft. Total sales fell 2.4% and organic sales were down 5.3% (calendar effects adjusted), while EBITA margin (ex items affecting comparability) was 6.7% and in line with last year. Management attributed the weak sales to strategic capacity adjustments from its restructuring agenda, while emphasizing a shift toward organic growth.

Analysis

This reads like a classic “bottoming but not yet monetizing” setup. The market should care less about the backlog headline and more about whether higher utilization is durable enough to turn into incremental EBITA without further price discounting; until revenue turns, the improvement mostly protects downside rather than drives upside. In other words, AFRY is moving from self-help to real demand recovery, and that second step is what usually gets the multiple.

The important second-order effect is competitive discipline: after a completed restructuring, AFRY can bid more selectively and should be less vulnerable to wage inflation than peers still carrying excess capacity. But if the revenue line keeps lagging, the firm risks winning lower-quality work or delaying the full benefit of the cost reset, which caps operating leverage. That makes this more relevant for patience in the 6-18 month window than for an immediate re-rating over the next few days.

Consensus may be underestimating how much of the story is already priced in if investors extrapolate backlog into growth. The key falsifier is simple: if organic sales stays negative for another quarter or two, or if utilization stalls before margin expands, the market will treat this as a cost-cut story with limited torque. Conversely, sustained positive organic growth would be the first real signal that the restructuring is finally translating into earnings power rather than just preventing further deterioration.

Key Decisions for Investors

• Do not initiate a fresh long in AFXXF here; wait for at least one quarter of positive organic growth and evidence that backlog is converting into revenue rather than just stabilizing the denominator.
• Use any post-earnings strength in AFXXF to fade the move tactically if the stock gaps higher without guidance upside; the near-term risk/reward favors underweighting a lagging-recovery name over chasing a backlog story.
• Set a hard alert on the next print: if utilization rolls over again or organic sales remain negative, move to a short/underweight in AFXXF because the restructuring benefit is then likely fully reflected and estimate cuts can resume.